DRUG DISCOVERY TODAY is a premier journal published by Elsevier Science Ltd, providing a vital platform for researchers, professionals, and students dedicated to the fields of drug discovery and pharmacology. With the ISSN 1359-6446 and E-ISSN 1878-5832, this esteemed journal has positioned itself at the forefront of scientific literature since its inception in 1996, boasting an impressive convergence set to last until 2024. Recognized for its rigorous peer-review process and high-quality publications, DRUG DISCOVERY TODAY attained a prestigious Q1 ranking in both Drug Discovery and Pharmacology categories for 2023, reflecting its significant impact and relevance in the field. With Scopus rankings placing it within the top percentile, at ranks #9 in Drug Discovery and #17 in Pharmacology out of over 300 journals, this journal serves as a crucial resource for the latest advancements and innovations in drug development. Although it does not offer Open Access, its comprehensive scope encompasses the most recent research, reviews, and insights, making DRUG DISCOVERY TODAY an essential read for anyone seeking to advance their knowledge and practice in pharmaceutical sciences.

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.

YAKUGAKU ZASSHI - JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, published by the Pharmaceutical Society of Japan, is a key academic journal dedicated to advancing the field of pharmaceutical sciences. Established in 1961 and set to contribute until 2024, this journal publishes original research articles, reviews, and clinical studies that encompass a wide spectrum of topics within pharmacology, toxicology, and pharmaceutics. Although the journal operates under a traditional subscription model, it maintains a recognized reputation with an impact factor that is steadily aligned within its category quartiles—ranking Q3 in Pharmaceutical Science and Q4 in Pharmacology as of 2023. With Scopus rankings reflecting its competitive standing, YAKUGAKU ZASSHI serves as a vital resource for researchers, professionals, and students looking to engage with innovative findings and broaden their understanding of pharmaceutical methodologies and research practices. With a current focus on bridging scientific research with real-world applications, it seeks to foster collaboration and knowledge sharing within the pharmaceutical community.

MINI-REVIEWS IN MEDICINAL CHEMISTRY is a distinguished journal published by Bentham Science Publishers, dedicated to the cutting-edge field of medicinal chemistry. With an ISSN of 1389-5575 and an E-ISSN of 1875-5607, this journal serves as an essential platform for researchers and professionals to disseminate concise yet comprehensive reviews that capture the latest advancements and trends in drug discovery, cancer research, pharmacology, and molecular medicine. Operating since 2001, it has consistently maintained a relevant presence in academia with its impressive rank metrics, including a Q2 category in Drug Discovery and Pharmacology in 2023, highlighting its significance in the scientific community. The journal is recognized for its rigorous peer-review process and provides an invaluable resource for students and researchers seeking insights into the rapidly evolving landscape of medicinal chemistry. With a commitment to excellence and innovation, MINI-REVIEWS IN MEDICINAL CHEMISTRY continues to foster knowledge exchange and inspire future breakthroughs in healthcare and therapeutic advancements.

Journal of Reports in Pharmaceutical Sciences is a pivotal publication in the realm of pharmaceutical research, disseminating innovative findings that cater to the evolving landscape of pharmacology, toxicology, and biomedical engineering. Published by Wolters Kluwer Medknow Publications, the journal serves as a bridge for scholars and practitioners aiming to enhance their understanding of drug development, therapeutic advances, and biopharmaceutical technologies. With an ISSN of 2322-1232 and E-ISSN 2322-5106, it has established its relevance from 2012 to 2022, occupying notable quartile rankings, including Q3 in Pharmacology, Toxicology, and Pharmaceutics. Despite being categorized in Q4 in some areas, the journal's commitment to quality research ensures it remains a respected platform for disseminating significant insights. Researchers, professionals, and students alike will find this journal an indispensable resource for staying updated on critical advancements in pharmaceutical sciences, making it a go-to source for impactful studies that shape industry practices and academic inquiries.

Recent Patents on Anti-Cancer Drug Discovery, published by Bentham Science Publishers Ltd, is an esteemed peer-reviewed journal specializing in the innovative intersection of pharmaceutical science and oncology. With an ISSN of 1574-8928 and an E-ISSN of 2212-3970, this journal aims to provide a comprehensive platform for the dissemination of recent developments in anti-cancer drug discovery, addressing critical issues and breakthroughs that influence cancer research and treatment. The journal spans from 2006 to 2024 and is indexed in several prestigious databases, showcasing its relevance with a Q3 ranking in key categories such as Cancer Research and Drug Discovery as of 2023. Its status of being open access reflects a commitment to making valuable scientific findings widely available, promoting collaboration and advancement in the field. With a dedicated focus on advancing knowledge in cancer therapeutics, the journal serves as a vital resource for researchers, healthcare professionals, and students aiming to contribute to the fight against cancer.

PHARMACIA is a distinguished open-access journal, published by PENSOFT PUBLISHERS, that has been a pivotal platform for advancing the field of pharmaceutical sciences since 2007. This journal, with ISSN 0428-0296 and E-ISSN 2603-557X, is based in Bulgaria and continues to publish high-quality research and reviews relevant to pharmacy, pharmacology, and toxicology. Recognized in the Q3 category for Pharmaceutical Sciences and Pharmacology (medical), as well as Q2 in Pharmacy according to the latest rankings, PHARMACIA is celebrated for its commitment to fostering knowledge dissemination and innovation in drug development, therapeutic approaches, and pharmacological research. With a Scopus rank of #17 in Pharmacy and recognition in various health professions, the journal attracts contributions from researchers, professionals, and students seeking to impact the pharmaceutical landscape. Its convenient open-access format ensures that articles are readily available to a global audience, encouraging collaboration and advancement in the life sciences.

Advances in Pharmacological and Pharmaceutical Sciences is a premier open-access journal published by Hindawi Ltd. based in the United Kingdom. Established in 2020, the journal swiftly garnered attention for its commitment to disseminating high-quality research in the realms of pharmacology, toxicology, and pharmaceutical sciences. It holds a commendable impact with notable quartile rankings, including Q2 in both Organic Chemistry and Pharmacology, indicating its importance within these disciplines. By embracing an open-access model, the journal ensures that research findings are widely available, promoting increased visibility and collaboration among researchers, professionals, and students globally. With an ongoing convergence of insights projected through 2024, Advances in Pharmacological and Pharmaceutical Sciences aims to address critical issues and advancements in drug development and therapeutic practices, making it an invaluable resource for those at the forefront of scientific inquiry in pharmacology and related fields.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, published by LIPPINCOTT WILLIAMS & WILKINS, is a leading peer-reviewed journal dedicated to the exploration and advancement of pharmacological therapies related to cardiovascular diseases. With its ISSN 0160-2446 and E-ISSN 1533-4023, this esteemed journal has been at the forefront of cardiovascular research since its inception in 1979, continuously offering insights until 2024. It holds a commendable position in the 2023 category quartiles, classified as Q2 in both Cardiology and Cardiovascular Medicine, as well as Medicine (miscellaneous) and Pharmacology, showcasing its significance within these fields. The journal presents a unique platform for researchers, health professionals, and students to disseminate their findings, fostering an environment of knowledge growth and collaboration in cardiovascular pharmacology. Readers can expect to find high-quality articles that contribute to the body of knowledge in cardiovascular therapies, ensuring they remain informed of the latest advancements and clinical practices. Discover more about this influential publication and its commitment to enhancing cardiovascular health.

Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.